RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pharmaceutical portfolio management groups lead financial reviews for developmental compounds at 70% of surveyed drug companies, according to a study by Cutting Edge Information.
“Business development teams make for an effective partner in these discussions because they spend significant time investigating potential in-licensing deals”
To successfully build a product portfolio that matches corporate goals, companies must evaluate developmental compounds. Not only must new compounds fit within a company’s existing therapeutic areas, they must also offer potential financial returns.
Cutting Edge Information’s study, “Pharmaceutical Portfolio Management: Selecting Targets, Filling Pipelines and Preparing for Post-Launch Success,” found that portfolio management groups did not work alone in performing financial calculations for developmental compounds. In fact, 67% of surveyed companies reportedly also involved of business development team.
“Business development teams make for an effective partner in these discussions because they spend significant time investigating potential in-licensing deals,” said Michelle Vitko, senior research analyst at Cutting Edge Information.
Cross-functional efforts extend to many other groups as well. At nearly half of surveyed companies (47%), market research teams aid portfolio management groups by offering an expansive view of the relevant marketplace. Marketing teams at 43% of companies surveyed typically forecast the compound’s commercial implications based on market research findings.
Some surveyed companies involved more teams in their compounds’ financial analysis. Clinical teams aided portfolio management teams at 33% of companies. Brand teams (13%) and medical affairs groups (10%) also assisted in comparatively fewer instances.
Cutting Edge Information’s study, “Pharmaceutical Portfolio Management: Selecting Targets, Filling Pipelines and Preparing for Post-Launch Success” (http://www.cuttingedgeinfo.com/research/portfolio-management/strategy-resources/) bridges the gap between clinical portfolio management and brand lifecycle management. The reports data benchmarks top-performing companies’ structures, budgets and outsourcing, and explores 13 lifecycle extension strategies. Use this report to:
- Drive portfolio management no matter your company size and resources.
- Improve cross-functional communication to build strategy and drive coordinated execution.
- Understand how others approach myriad issues facing decision makers, such as troubled pipelines, slow approvals and challenging reimbursement.
For more information about pharmaceutical portfolio management, contact Cassie Demeter at +1 919-403-6583.